A detailed history of Raymond James & Associates transactions in Aurinia Pharmaceuticals Inc. stock. As of the latest transaction made, Raymond James & Associates holds 17,701 shares of AUPH stock, worth $99,656. This represents 0.0% of its overall portfolio holdings.

Number of Shares
17,701
Previous 18,101 2.21%
Holding current value
$99,656
Previous $162,000 45.68%
% of portfolio
0.0%
Previous 0.0%

Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 22, 2024

SELL
$4.93 - $9.31 $1,972 - $3,724
-400 Reduced 2.21%
17,701 $88,000
Q4 2023

Jan 16, 2024

BUY
$7.13 - $9.49 $8,199 - $10,913
1,150 Added 6.78%
18,101 $162,000
Q3 2023

Oct 24, 2023

BUY
$7.77 - $12.27 $36,138 - $57,067
4,651 Added 37.81%
16,951 $131,000
Q2 2023

Jul 25, 2023

BUY
$8.96 - $11.69 $4,480 - $5,845
500 Added 4.24%
12,300 $119,000
Q1 2023

Apr 14, 2023

BUY
$5.94 - $11.27 $70,092 - $132,986
11,800 New
11,800 $129,000
Q2 2022

Aug 12, 2022

SELL
$8.95 - $12.8 $101,134 - $144,640
-11,300 Closed
0 $0
Q1 2022

May 11, 2022

BUY
$10.05 - $22.48 $113,565 - $254,024
11,300 New
11,300 $140,000
Q4 2021

Feb 08, 2022

SELL
$17.78 - $33.08 $224,028 - $416,808
-12,600 Closed
0 $0
Q3 2021

Nov 02, 2021

SELL
$10.93 - $23.55 $168,212 - $362,434
-15,390 Reduced 54.98%
12,600 $279,000
Q2 2021

Aug 11, 2021

BUY
$10.0 - $14.52 $279,900 - $406,414
27,990 New
27,990 $363,000
Q1 2021

May 14, 2021

SELL
$12.3 - $18.73 $132,225 - $201,347
-10,750 Closed
0 $0
Q4 2020

Feb 12, 2021

BUY
$12.94 - $16.05 $139,105 - $172,537
10,750 New
10,750 $149,000
Q2 2020

Jul 28, 2020

SELL
$14.12 - $18.33 $585,909 - $760,603
-41,495 Closed
0 $0
Q1 2020

Apr 21, 2020

BUY
$11.34 - $21.46 $147,987 - $280,053
13,050 Added 45.88%
41,495 $602,000
Q4 2019

Feb 12, 2020

BUY
$3.88 - $21.42 $110,366 - $609,291
28,445 New
28,445 $576,000
Q3 2017

Nov 13, 2017

SELL
$5.71 - $6.9 $165,590 - $200,100
-29,000 Closed
0 $0
Q2 2017

Aug 14, 2017

BUY
N/A
29,000
29,000 $178,000

Others Institutions Holding AUPH

About Aurinia Pharmaceuticals Inc.


  • Ticker AUPH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 141,892,000
  • Market Cap $799M
  • Description
  • Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license...
More about AUPH
Track This Portfolio

Track Raymond James & Associates Portfolio

Follow Raymond James & Associates and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.